In order to stand out of the world, one has to achieve something, which has not yet been developed or is better than its previous counterpart. Same is the case with pharmaceutical industries.

Experts suggest that these companies are always in a benefit if they develop drugs that are better in their clinical properties than that provide by the already existing drugs.

However, the other part of the story has a dark end to it. Professor Donald Light from the University of Medicine and Dentistry of New Jersey and Joel Lexchin from York University in Toronto emphasized that due to the fear of failure since the past five decades almost innovation has been put to an end.

They considered independent reviews of the past 50 years, which highlighted that all the drugs manufactured, out of them 85% to 90% were not able to provide with as much benefits as harms were administered.

They said, "Most research funds don't go towards finding breakthrough drugs but towards developing scores of minor variations that produce a steady stream of profits".

Further, they added that 80% of the finances diverted by the nation towards drug development are lost during its heavy promotion. They warned that majority of the companies lay more stress on the costs incurred for their research and development.